Message : Required fields BARCELONA, May 10 (Reuters) - Spanish pharmaceuticals group Almirall said on Monday its first-quarter net profit fell 38.7% to 29.8 million euros ($36.2 million) and revenues by 10%, as the company looks for merger and acquisition (M&A) opportunities. The Barcelona-based firm continued to be hurt by the pandemic as mobility restrictions led to fewer patients going to the doctor, while sales suffered from generic competition in the United States. It said on Monday it predicts COVID-19 will continue to affect its operations in the first half, before its impact lessens in the second half of the year. With Gianfranco Nazzi recently sworn as chief executive